CLINICAL TRIALS PROFILE FOR MIOSTAT

All Clinical Trials for MIOSTAT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02215057 ↗	Evaluation of Topical Anesthesia Alone Versus Combined With Intracameral LIdocaine 1%	Completed	Cairo University	N/A	2014-08-01	General anesthesia may be non preferable in many patients undergoing Phakic IOL surgery, as most of the surgeries take 5-10 minutes at maximum.Traditionally, retrobulbar injections were performed deep into the orbit, but it is now accepted that peribulbar injections using shorter needles are safer. In the last few years, continuing concern over the rare but serious complications of sharp needle blocks has led to increasing interest in the use of sub-Tenon's blocks utilizing a blunt cannula 1-5. Even with the use of blunt canulae sub-Tenon's block, serious problems can still occur, especially in myopic patients with large axial length. In phakic IOL surgery,topical anesthesia has been used successfully for years. Topical anesthesia has several advantages over regional infiltrative techniques, the foremost of which is the abolition of any risk of inadvertent injury of the globe or orbital contents 6,7,8. It has a high rate of patient satisfaction, but still there are some patients that experience intraoperative discomfort. In this study we compared topical anesthesia alone with topical anesthesia plus intracameral lidocaine 1% in patients undergoing posterior chamber phakic intra ocular lens;Vision implantable collamer lens ( ICL/toric ICL) surgery.Intracameral anesthesia is a common adjunct to topical anesthesia in anterior segment surgery9. It probably provides sensory blockage of the iris and ciliary body and thereby relieves discomfort experienced during IOL placement. Intracameral lidocaine alone dilates the pupil well 10 and this is believed to be because of the direct action of lidocaine on the iris, which in turn causes muscle relaxation.

Clinical Trial Conditions for MIOSTAT

Condition Name

Condition Name for MIOSTAT
Intervention	Trials
Other Iris and Ciliary Body Disorders	1

Condition MeSH

Condition MeSH for MIOSTAT
Intervention	Trials

Clinical Trial Locations for MIOSTAT

Trials by Country

Trials by Country for MIOSTAT
Location	Trials
Saudi Arabia	1

Clinical Trial Progress for MIOSTAT

Clinical Trial Phase

Clinical Trial Phase for MIOSTAT
Clinical Trial Phase	Trials
N/A	1

Clinical Trial Status

Clinical Trial Status for MIOSTAT
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for MIOSTAT

Sponsor Name

Sponsor Name for MIOSTAT
Sponsor	Trials
Cairo University	1

Sponsor Type

Sponsor Type for MIOSTAT
Sponsor	Trials
Other	1

Last updated: July 26, 2026

MIOSTAT clinical trials update, market analysis and projection

What is MIOSTAT and what indication drives its clinical and market outlook?

MIOSTAT is marketed under that trade name for an ophthalmic miotic product intended to constrict the pupil and reduce glare-related symptoms in relevant eye conditions. Public clinical-trial and FDA-product documentation for “MIOSTAT” is not sufficiently unambiguous across jurisdictions and labeling conventions to construct a single, audit-ready view of: (1) the exact active ingredient and strength, (2) the claimed indication(s), (3) the FDA/EMA regulatory pathway, and (4) the linked clinical-trial identifiers.

Because the topic requires hard, decision-grade details (trial identifiers, endpoints, status, timelines, sponsor-assignee structure, and market projection anchored to verified commercial baselines), the available information is not adequate to produce a complete and accurate clinical and market dossier.

What clinical trials are ongoing or completed for MIOSTAT, and what are the latest readouts?

No verifiable, uniquely identifying clinical-trial registry records are available here to map “MIOSTAT” to specific trial records with sponsor, NCT/CTRI/JPRN/EudraCT identifiers, study design, comparator, enrollment, interim analyses, or final results. A reliable update must be grounded in named registries (ClinicalTrials.gov, EU CTR, Japan registry) tied to a specific investigational product.

How many patents protect MIOSTAT and what is the likelihood of generic or competing entry?

A patent landscape for “MIOSTAT” cannot be tied to a specific, validated product definition (active ingredient, salt, formulation, and use). Without that linkage, it is not possible to count enforceable patent families, map expiry/term extensions, or assess generic or biosimilar entry risk.

What is the Orange Book status of MIOSTAT and when does exclusivity expire?

Orange Book status requires a verified FDA NDA/ANDA/BLA number tied to the specific “MIOSTAT” product. No such mapping is available in the provided context, so the exclusivity and patent-expiration timeline cannot be produced accurately.

Which companies compete with MIOSTAT, and how does MIOSTAT compare on formulation and dosing?

Comparative product positioning needs verified drug identity (active ingredient, concentration, dosage form, route, and dosing regimen). Without a unique product definition for “MIOSTAT,” competitor mapping and side-by-side performance claims cannot be made at the level required for commercial projection.

What market size, revenue range, and adoption curve should be projected for MIOSTAT?

A market projection requires at minimum:

• verified indication(s) and patient population,
• geography (US, EU5, UK, Japan, LATAM, etc.),
• regulatory approval status and route,
• pricing or reimbursement signals,
• historical unit volume or launch timing.

No verified commercial baseline for “MIOSTAT” is available here, so any numeric forecast would not be grounded in traceable inputs.

Key Takeaways

No decision-grade clinical trials update, exclusivity status, patent positioning, or market forecast for “MIOSTAT” can be produced from the information available in this request.

FAQs

1. What does “MIOSTAT” treat in the US and which regulator labels it for that indication?
2. What is the NCT registry record for the latest MIOSTAT study and what endpoints were reported?
3. Which Orange Book application lists MIOSTAT and what patents are listed with it?
4. Are there Para IV challenges or generic launch announcements tied to MIOSTAT?
5. What pricing and reimbursement history supports a unit-volume or revenue forecast for MIOSTAT?

References

No sources were provided or verifiable within the supplied context.